Status:
COMPLETED
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors
Lead Sponsor:
GlaxoSmithKline
Conditions:
Solid Tumours
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of GSK1363089 treatment in adults with solid tumors. This study is no longer recruiting subj...
Eligibility Criteria
Inclusion
- Histologically confirmed solid tumor which is metastatic or unresectable with no known effective treatment measures,
- ECOG performance status of \</= 2.
- Adequate bone marrow reserve, hepatic, renal, and cardiovascular function,
- Negative pregnancy test.
Exclusion
- Chemotherapy within 4-6 weeks of the start of treatment,
- Radiotherapy within 4 weeks of the start of treatment,
- Known brain metastasis,
- Uncontrolled medical disorder such as infection or cardiovascular disease,
- HIV positive,
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
March 17 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 29 2011
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00742131
Start Date
March 17 2005
End Date
August 29 2011
Last Update
July 31 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.